FDA-approved
Hormones & metabolism
Elamipretide
Evidence
FDA approved
Class
Mitochondria-targeted tetrapeptide
KEY TAKEAWAY
Elamipretide is a small four-amino-acid peptide that concentrates in mitochondria and binds a lipid called cardiolipin. It is sold as Forzinity. The FDA granted accelerated approval to elamipretide (Forzinity) in 2025 for Barth syndrome. Continued approval depends on confirmatory evidence.
Written by the Veylo editorial team · Updated
November 2026
What it is
Mitochondria-targeted tetrapeptide
Approved for
Barth syndrome
Key fact
The FDA granted accelerated approval to elamipretide (Forzinity) in 2025 for Barth syndrome. Continued approval depends on confirmatory evidence.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Elamipretide is a small four-amino-acid peptide that concentrates in mitochondria and binds a lipid called cardiolipin. It is sold as Forzinity.
By binding cardiolipin, it is thought to stabilize the inner mitochondrial membrane and help cells make energy more efficiently.
The FDA granted accelerated approval to elamipretide (Forzinity) in 2025 for Barth syndrome. Continued approval depends on confirmatory evidence.
Barth syndrome.
Injection-site reactions were the most common side effects.
U.S. FDA prescribing information for Elamipretide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.